AZASITE

LOE Approaching

azithromycin monohydrate

NDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12

Mechanism of Action

12.1 Mechanism of Action Azithromycin is a macrolide antibiotic [see ] . 12.3 Pharmacokinetics The plasma concentration of azithromycin following ocular administration of AzaSite (azithromycin ophthalmic solution) in humans is unknown. Based on the proposed dose of one drop to each eye (total dose…

Clinical Trials (5)

NCT01797107Phase 2Withdrawn

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

Started Mar 2013
0
Meibomian Gland Dysfunction
NCT01102244Phase 3Completed

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Started Apr 2010
122 enrolled
Blepharitis
NCT00656539Phase 4Completed

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

Started Apr 2008
20 enrolled
Blepharitis
NCT00629941Phase 4Completed

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

Started Mar 2008
25 enrolled
Blepharitis
NCT00629590Phase 4Completed

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

Started Mar 2008
20 enrolled
Blepharitis